Skip to main content
    S

    SIGA Technologies Inc (SIGA)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $2.85
    +0.11 (+4.01%)

    Market Cap: $196.88M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    SIGA Technologies Inc (SIGA) Earnings: Report Dates and Results

    Updated Nov 9, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    SIGA Technologies (SIGA) is expected to report earnings on Mar 8, 2027. In the quarter ended Sep 30, 2026, SIGA Technologies reported EPS of -$0.04. It beat the EPS estimate in 2 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    18%(2/11)
    Avg Surprise
    +0.29%
    Streak
    2 Q

    Next Report

    SIGA has an expected report date of Mar 8, 2027.

    SIGA Earnings Call

    The latest SIGA earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 11 quarters below that had an estimate, SIGA beat 2 and matched 9. Revenue for the quarter ended Sep 30, 2026 was $1.32M, down 49.6% from $2.62M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.04N/AN/AN/AN/AN/AN/AN/ANov 9, 2026$1.32M
    Jun 30, 2026$0.17N/AN/AN/AN/A-65.3%N/AN/AAug 6, 2026$41.00M
    Mar 31, 2026-$0.05N/AN/AN/AN/AN/AN/AN/AMay 7, 2026$6.24M
    Dec 31, 2025-$0.08N/AN/AN/AN/A-111.8%N/AN/AMar 10, 2026$3.80M
    Sep 30, 2025-$0.09N/AN/AN/AN/A-575.4%N/AN/ANov 6, 2025$2.62M
    Jun 30, 2025$0.49N/AN/AN/AN/A+1821.6%N/AN/AAug 5, 2025$81.12M
    Mar 31, 2025-$0.01N/AN/AN/AN/A-104.0%N/A0 up, 0 downMay 8, 2025$7.04M
    Dec 31, 2024$0.64N/AN/AN/AN/A-36.9%N/A0 up, 0 downMar 11, 2025$81.47M
    Sep 30, 2024$0.02N/AN/AN/AN/AN/AN/A0 up, 0 downNov 7, 2024$10.01M
    Jun 30, 2024$0.03N/AN/AN/AN/AN/AN/A0 up, 0 downAug 1, 2024$21.81M
    Mar 31, 2024$0.14$0.14N/A+2.57%BeatN/AN/A0 up, 0 downMay 7, 2024$25.43M
    Dec 31, 2023$1.02$1.01N/A+0.63%BeatN/AN/A0 up, 0 downMar 12, 2024$116.48M
    Sep 30, 2023-$0.01-$0.01N/A0.00%In line-102.2%N/A0 up, 0 downNov 7, 2023$9.24M
    Jun 30, 2023-$0.04-$0.04N/A0.00%In line-233.3%N/A0 up, 0 downAug 8, 2023$5.88M
    Mar 31, 2023-$0.01-$0.01N/A0.00%In lineN/AN/A0 up, 0 downMay 4, 2023$8.32M
    Dec 31, 2022-$0.01-$0.01N/A0.00%In line-101.0%N/A0 up, 0 downMar 2, 2023$11.36M
    Sep 30, 2022$0.45$0.45N/A0.00%In lineN/AN/A0 up, 0 downNov 3, 2022$72.21M
    Jun 30, 2022$0.03$0.03N/A0.00%In lineN/AN/A0 up, 0 downAug 4, 2022$16.67M
    Mar 31, 2022-$0.01-$0.01N/A0.00%In lineN/AN/A0 up, 0 downMay 5, 2022$10.54M
    Dec 31, 2021$0.98$0.98N/A0.00%In line+276.9%N/A0 up, 0 downMar 3, 2022$115.36M
    Sep 30, 2021-$0.04-$0.04N/A0.00%In line-112.9%N/AN/ANov 4, 2021$4.85M
    Jun 30, 2021$0.00N/AN/AN/AN/A-101.3%N/AN/AAug 5, 2021$8.65M
    Mar 31, 2021-$0.02N/AN/AN/AN/AN/AN/AN/AMay 6, 2021$4.81M
    Dec 31, 2020$0.26N/AN/AN/AN/AN/AN/AN/AMar 4, 2021$37.73M
    Sep 30, 2020$0.31N/AN/AN/AN/AN/AN/AN/ANov 5, 2020$44.26M
    Jun 30, 2020$0.26N/AN/AN/AN/AN/AN/AN/AAug 6, 2020$40.35M
    Mar 31, 2020-$0.11N/AN/AN/AN/A-650.0%N/AN/AMay 6, 2020$2.62M
    Dec 31, 2019-$0.15N/AN/AN/AN/A-123.1%N/AN/AMar 5, 2020$4.26M
    Sep 30, 2019-$0.01N/AN/AN/AN/A-100.2%N/AN/ANov 5, 2019$8.11M
    Jun 30, 2019-$0.04N/AN/AN/AN/AN/AN/AN/AAug 6, 2019$3.91M
    Mar 31, 2019$0.02N/AN/AN/AN/AN/AN/AN/AMay 2, 2019$10.46M
    Dec 31, 2018$0.65N/AN/AN/AN/AN/AN/AN/AMar 5, 2019$1.57M
    Sep 30, 2018$4.71N/AN/AN/AN/AN/AN/AN/ANov 6, 2018$471.08M
    Jun 30, 2018-$0.09N/AN/AN/AN/AN/AN/AN/AAug 7, 2018$2.66M
    Mar 31, 2018-$0.15N/AN/AN/AN/AN/AN/AN/AMay 4, 2018$1.75M
    Dec 31, 2017-$0.16N/AN/AN/AN/AN/AN/AN/AMar 6, 2018$1.41M
    Sep 30, 2017-$0.12N/AN/AN/AN/AN/AN/AN/ANov 7, 2017$1.39M
    Jun 30, 2017-$0.10N/AN/AN/AN/AN/AN/AN/AAug 3, 2017$4.26M
    Mar 31, 2017-$0.11N/AN/AN/AN/AN/AN/AN/AMay 4, 2017$5.20M
    Dec 31, 2016-$0.11N/AN/AN/AN/AN/AN/AN/AMar 7, 2017$7.16M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.32, down 61.4% from the year before. It was -$0.61 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.32-61.4%
    Dec 31, 2024$0.83-13.4%
    Dec 31, 2023$0.96+107.9%
    Dec 31, 2022$0.46-49.8%
    Dec 31, 2021$0.92+27.3%
    Dec 31, 2020$0.72N/A
    Dec 31, 2019-$0.18-103.5%
    Dec 31, 2018$5.12N/A
    Dec 31, 2017-$0.49N/A
    Dec 31, 2016-$0.61N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 2,400 words across 4 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20262,3894
    2026Q2Jun 30, 20261,9304
    2026Q1Mar 31, 20262,3054
    2025Q3Sep 30, 20252,6134
    2025Q2Jun 30, 20252,7784
    2025Q1Mar 31, 20252,6994
    2024Q4Dec 31, 20244,6455
    2024Q3Sep 30, 20243,2594

    2026Q3 Earnings Call

    Opening remarks

    Diem Nguyen CEO Good afternoon, everyone, and thank you for joining today's call to review our business results. I am joined by Dan Luckshire, our Chief Financial Officer, and we appreciate this opportunity to provide an update on our company. After the update, we will take your questions. Throughout 2026, SIGA has continued to execute on its core mission of working alongside governments to build and sustain long-term preparedness against potential biological threats, namely smallpox. We remain committed to positioning our smallpox therapeutic, TPOXX, for rapid, large-scale deployment should an outbreak occur. As a reminder, in the second quarter, we completed our final product delivery under the BARDA 19C contract, fulfilling all our product obligations under that agreement. We are proud of this partnership, proud of how we performed, and proud to have played an important role in strengthening the U.S. government's smallpox preparedness. We believe the case for preparedness against biological threats remains strong. Geopolitical tensions and advances in technology, including AI, are reshaping the threat landscape. Mitigating these risks requires proactive, sustained government investment in medical countermeasures stockpiles. In an emergency, ready access to medical countermeasures is essential to protect both civilians and warfighters. At the same time, a compelling case for preparedness does not always translate into predictable procurement. As we discussed during our last call, the process to secure a new U.S. government contract has progressed more slowly than in the past, and the timing of an award remains uncertain. Even so, we remain confident that TPOXX has an important role in our nation's preparedness plans and that national security for medical countermeasures remains important to the U.S. government. Despite the lack of certainty as to timing and details, based on our discussions with key stakeholders, we continue to believe that a new procurement contract will be awarded. Turning to our international business, I would like to share news of a recent contract that advances our efforts to maintain a diverse revenue stream and customer base. Last month, we signed a contract to supply oral TPOXX to Canada's Department of National Defence, or CDND, over the next five years. This contract is valued at up to approximately $15 million. It includes firm commitments of about $9 million over the first three years, plus up to $6 million in options exercisable at CDND's discretion. This is CDND's second TPOXX contract. The first, awarded in April 2020 for the purchase of up to approximately $14 million of TPOXX, was completed in 2025. Canada continues to be one of the leaders in smallpox preparedness among our international customers, and we believe this award reflects that commitment. It also highlights another important point.

    Frequently Asked Questions About SIGA

    When is SIGA Technologies's next earnings date?

    SIGA Technologies's next earnings report is expected for Mar 8, 2027.

    How often does SIGA beat earnings estimates?

    SIGA Technologies beat the EPS estimate in 2 of the 8 most recent quarters that had an estimate, with an average surprise of +0.40%.